Jpmorgan Chase & CO Avalo Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.0 - $10.45 $82,155 - $286,173	-27,385 Reduced 93.68%	1,848 $1,000
Q1 2022 May 11, 2022	SELL	$7.57 - $21.72 $145,995 - $418,891	-19,286 Reduced 39.75%	29,233 $21,000
Q4 2021 Feb 10, 2022	BUY	$19.68 - $28.68 $553,362 - $806,424	28,118 Added 137.83%	48,519 $83,000
Q3 2021 Nov 12, 2021	BUY	$26.16 - $40.68 $533,690 - $829,912	20,401 New	20,401 $44,000

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $118M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.